Építés alatt – nem éles oldal
Belépés

NCT07864168Toboroz

Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. okt. 20.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

This study will collect sensor data in subjects with T1D or T2D, 2-80 years of age.

Állapot (regiszter)
Toboroz
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
1500 (tervezett)
Első benyújtás
2026. szept. 28.
Kezdés
2026. okt. 5.
Elsődleges befejezés
2027. dec.
Fő szponzor
Medtronic MiniMed, Inc.
NCT-szám
NCT07864168

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó
  • Tervezett résztvevők: 1500
  • 2026. okt. 5. és az elsődleges befejezés (2027. dec.) között
  • 17 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Has a history of 1 or more episodes of severe hypoglycemia during the 6 months prior to screening visit.
  • Has had a hypoglycemic seizure within the past 6 months prior to screening visit.
  • Has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to enrollment.
  • Has a history of 1 or more episodes of DKA in the last 6 months prior to screening visit.
  • T2D: Has had hyperglycemic hyperosmolar syndrome (HHS) in the last 6 months prior to screening visit.
  • Has a planned procedure involving the use of a Magnetic Resonance Imaging (MRI), diathermy devices, or other devices that generate strong magnetic fields (e.g., x-ray, CT scan, or other types of radiation) during the study wear period.
  • Has elective surgery planned that requires general anesthesia during the course of the study.
  • Is, at the discretion of the investigator, abusing drugs or alcohol
  • Age 7-80 years: has a hematocrit (Hct) more than 10% below the lower limit of normal reference range (please note that prior blood draw from routine care may be used as long as the prior blood draw was done within 3 months prior to screening and report of lab placed with subject source documents).

Más betegség

  • Has a history of a seizure disorder.
  • Has a central nervous system or cardiac disorder resulting in syncope.
  • Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).
  • Has diagnosis of adrenal insufficiency.
  • Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.
  • Has any other disease or condition that may preclude the patient from participating in the study, per investigator judgment.

Laborértékek

  • Has had any of the following cardiovascular events more than 1 year prior to screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances. However, subject may participate at the discretion of the investigator and with clearance from the cardiologist.

Egyéb

  • Unable to consent due to a mental or intellectual disability.
  • Will not tolerate tape adhesive in the area of sensor placement as assessed by a qualified individual.
  • Currently pregnant or planning to become pregnant during the time period of study participation
    • A negative pregnancy test will be required for all females of child-bearing potential at time of screening
    • For sexually active females of child-bearing potential the investigator will use discretion to determine if the form of contraception that is being used is reliable
  • Is using hydroxyurea at time of screening or plans to use it during the study.
  • Is participating in another pharmaceutical or device trial within 2 weeks of enrollment or anticipates participation in another trial during the course of the study. (Please note participation in an observational study is acceptable.)
  • T2D: Is using insulin secretagogue.
  • Is a member of the research staff involved with the study.
  • Is a sponsor employee or their immediate family member (excluding adult children and/or adult siblings).

Kiket keres a vizsgálat

  • Age 2-80 years at time of screening.
  • Has a clinical diagnosis of diabetes as stipulated according to the following age group:
    • Age 2-10 years: Has a clinical diagnosis of T1D or T2D as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis.
    • Age 11-80 years: Has a clinical diagnosis of T1D or T2D for 6 months or more, as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.
  • Subject or parent(s)/ guardian(s)/ caregiver(s) is/are literate and able to read the language offered in the study materials.
  • Is willing to provide informed consent/assent for participation.
  • If participating in BGA FST, has adequate venous access as assessed by investigator or appropriate staff.
  • Is willing to perform fingerstick blood glucose measurements as needed.
  • Is willing to wear the study devices continuously throughout the study.
  • Subject or parent(s)/guardian(s)/caregiver(s) is/are willing to complete the requirements for diary data entry, as applicable.
  • If participating in glycemic challenges, has met the following conditions:
    • Been using insulin for at least 3 months
    • A relatively stable insulin-to-carbohydrate ratio(s) and insulin sensitivity factor(s) for at least one month per investigator assessment Subjects who do not meet the above conditions can be included in the study, however, will participate in the FST under observation only (no glycemic challenges).

Életkor a regiszterben: 2 év – 80 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (17)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Atlanta Diabetes AssociatesAtlantaEgyesült ÁllamokToboroz
Barbara Davis Center for DiabetesAuroraEgyesült ÁllamokToboroz
Texas Diabetes and EndocrinologyAustinEgyesült ÁllamokToboroz
University of Virginia Health SystemCharlottesvilleEgyesült ÁllamokToboroz
ProScientoChula VistaEgyesült ÁllamokToboroz
University of FloridaGainesvilleEgyesült ÁllamokToborzás még nem indult
Rocky Mountain Clinical ResearchIdaho FallsEgyesült ÁllamokToboroz
Yale University School Of MedicineNew HavenEgyesült ÁllamokToborzás még nem indult
Stanford UniversityPalo AltoEgyesült ÁllamokToborzás még nem indult
Rainier Clinical Research CenterRentonEgyesült ÁllamokToboroz
Diabetes and Glandular Disease ClinicSan AntonioEgyesült ÁllamokToboroz
Rady Children's Hospital - San DiegoSan DiegoEgyesült ÁllamokToborzás még nem indult
University of California San Francisco UCSF The Madison Clinic for Pediatric DiabetesSan FranciscoEgyesült ÁllamokToborzás még nem indult
Sansum Diabetes Research InstituteSanta BarbaraEgyesült ÁllamokToboroz
Seattle Children'sSeattleEgyesült ÁllamokToborzás még nem indult
University of South Florida (USF) Diabetes and Endocrinology CenterTampaEgyesült ÁllamokToborzás még nem indult
Diablo Clinical Research, Inc.Walnut CreekEgyesült ÁllamokToboroz

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.